ClinicalTrials.gg
CompletedNCT05666310MITOUpdated Oct 27, 2026Results posted

Muscle Impact of Treating Osteoporosis

A Phase 4 interventional study of Denosumab and Zoledronic Acid in Sarcopenia and Osteoporosis, sponsored by Nami Safai Haeri. Completed at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Nami Safai Haeri · Phase 4, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now CompletedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Sarcopenia with a site in United States — 36 open to participants now, 46 under way, 1 of them phase 3. Sarcopenia · United States.

Enrollment
110th of 146
20 · median 40
Started
2023
with 14 others
Phase 4
5 of 187
none open now
Registered
151st of 187
by date

Among the 187 studies in Sarcopenia with a site in United States, this one is the 110th largest by enrollment of the 146 interventional ones that give a count, is one of 15 that started in 2023, is one of 5 in phase 4, and was the 151st registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Sarcopenia with a site in United States, or all of them as a file.
02

Study summary

Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.

03

Conditions studied

  • Sarcopenia
  • Osteoporosis
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ambulatory adults age ≥65 years including those using assistive devices to maximize generalizability, if they have criteria for treating osteoporosis including:

  1. Osteoporosis by axial bone density (spine, hip or forearm BMD T-score ≤-2.5 SD) or
  2. A previous adult fragility fracture of the spine or hip or
  3. Would be treated based on FRAX National Osteoporosis Foundation treatment thresholds of a 10-year risk of ≥ 20% for a major osteoporotic fracture or ≥ 3% for hip fracture using femoral neck BMD.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a calculated \< 35 ml/min or
  2. Who have a for bisphosphonates or denosumab or
  3. Those who are scheduled for a tooth extraction to avoid jaw osteonecrosis or
  4. Subjects with severe liver disease or
  5. Those who have been on oral bisphosphonates for the past 1 year and intravenous bisphosphonates for the past 2 years prior to the study or
  6. Men
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Zoledronic Acid

    Zoledronic acid 5 mg IV infusion at month 0, with placebo subcutaneous injections at months 0 and 6. Open-label zoledronic acid 5 mg IV at month 12.

    Drug: Zoledronic Acid · Other: Denosumab Placebo

  • Active comparator
    Denosumab

    Denosumab 60 mg subcutaneous injection at months 0 and 6, with placebo IV infusion at month 0. Open-label zoledronic acid 5 mg IV at month 12.

    Drug: Denosumab · Other: Zoledronic Acid Placebo

Interventions

  • Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.

  • Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All participants will receive zoledronic acid 5 mg intravenous infusion at month 12.

  • OtherDenosumab Placebo

    Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.

  • OtherZoledronic Acid Placebo

    Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Urinary D3-creatinine Enrichment (D3-creatine Dilution)

    Muscle creatine pool size was estimated by D3-creatine dilution. Participants took a single 30 mg oral dose of deuterium-labeled creatine at baseline and 12 months, with a fasting morning urine sample collected approximately 72 hours later. Urinary D3-creatinine and total creatinine were measured by liquid chromatography-mass spectrometry. Enrichment is the " mol/mol ratio" of D3-creatinine to total creatinine in the same molar units, a dimensionless value from 0 to 1 (baseline values here were approximately 0.03, or 3%). Because about 95% of body creatine is in skeletal muscle, higher enrichment reflects less tracer dilution in a smaller pool and therefore less muscle mass. Reported values are the change (Month 12 minus Baseline), so a positive value is consistent with decreased muscle mass. Enrichment is reported rather than derived muscle mass because derived values showed high intra-individual variability.

    Time frame: Baseline vs Month 12

  2. Percentage Change From Baseline in Bone Mineral Density (BMD)

    BMD is measured by a DXA scan system and a higher BMD is correlated with lower fracture risk

    Time frame: Baseline vs Month 12

  3. Change From Baseline in Appendicular Lean Mass.

    Appendicular lean mass was measured by whole-body dual-energy X-ray absorptiometry and defined as the sum of lean soft tissue mass of both arms and both legs divided by height in meters squared "in kg/m²", excluding bone mineral content and fat mass. Values reported are the change (Month 12 minus Baseline) in appendicular lean mass index; a negative value indicates a decrease.

    Time frame: Baseline vs Month 12

  4. Change From Baseline in Grip Strength

    Grip strength is measure of muscle strength and will be measured by a standard hand dynamometer

    Time frame: Baseline vs Month 12

  5. Change From Baseline in 4-Meter Walk Time (Gait Speed)

    Gait speed is a measure of muscle function and will be measured by standard 4 meter gait speed test

    Time frame: Baseline vs Month 12

  6. Change From Baseline in Rectus Femoris Muscle Thickness (cm)

    This variable will be measured by ultrasound

    Time frame: Baseline vs Month 12

  7. Change From Baseline in Rectus Femoris Muscle Cross-sectional Surface Area (cm²)

    This variable will be measured by ultrasound

    Time frame: Baseline vs Month 12

  8. CTX Changes

    Marker of bone resorption

    Time frame: Baseline vs Month 12

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneDenosumabZoledronic Acid
Started1010
Completed910
Not completed10

Outcome measures

PrimaryChange From Baseline in Urinary D3-creatinine Enrichment (D3-creatine Dilution)

Muscle creatine pool size was estimated by D3-creatine dilution. Participants took a single 30 mg oral dose of deuterium-labeled creatine at baseline and 12 months, with a fasting morning urine sample collected approximately 72 hours later. Urinary D3-creatinine and total creatinine were measured by liquid chromatography-mass spectrometry. Enrichment is the " mol/mol ratio" of D3-creatinine to total creatinine in the same molar units, a dimensionless value from 0 to 1 (baseline values here were approximately 0.03, or 3%). Because about 95% of body creatine is in skeletal muscle, higher enrichment reflects less tracer dilution in a smaller pool and therefore less muscle mass. Reported values are the change (Month 12 minus Baseline), so a positive value is consistent with decreased muscle mass. Enrichment is reported rather than derived muscle mass because derived values showed high intra-individual variability.

Time frame:
Baseline vs Month 12
Reported as:
Mean · Ratio
Change From Baseline in Urinary D3-creatinine Enrichment (D3-creatine Dilution)
RatioDenosumabZoledronic Acid
Change From Baseline in Urinary D3-creatinine Enrichment (D3-creatine Dilution)0.005 ± 0.0060.001 ± 0.006
PrimaryPercentage Change From Baseline in Bone Mineral Density (BMD)

BMD is measured by a DXA scan system and a higher BMD is correlated with lower fracture risk

Time frame:
Baseline vs Month 12
Reported as:
Mean · percentage change
Percentage Change From Baseline in Bone Mineral Density (BMD)
percentage changeDenosumabZoledronic Acid
Lumbar Spine5.2 ± 3.24.9 ± 2.5
Total Hip3.2 ± 1.91.4 ± 1.2
Femoral Neck3.5 ± 3.50.2 ± 2.9
PrimaryChange From Baseline in Appendicular Lean Mass.

Appendicular lean mass was measured by whole-body dual-energy X-ray absorptiometry and defined as the sum of lean soft tissue mass of both arms and both legs divided by height in meters squared "in kg/m²", excluding bone mineral content and fat mass. Values reported are the change (Month 12 minus Baseline) in appendicular lean mass index; a negative value indicates a decrease.

Time frame:
Baseline vs Month 12
Reported as:
Mean · kg/m²
Change From Baseline in Appendicular Lean Mass.
kg/m²DenosumabZoledronic Acid
Change From Baseline in Appendicular Lean Mass.-0.049 ± 0.203-0.044 ± 0.282
PrimaryChange From Baseline in Grip Strength

Grip strength is measure of muscle strength and will be measured by a standard hand dynamometer

Time frame:
Baseline vs Month 12
Reported as:
Mean · kg
Change From Baseline in Grip Strength
kgDenosumabZoledronic Acid
Change From Baseline in Grip Strength1.39 ± 1.883.08 ± 3.00
PrimaryChange From Baseline in 4-Meter Walk Time (Gait Speed)

Gait speed is a measure of muscle function and will be measured by standard 4 meter gait speed test

Time frame:
Baseline vs Month 12
Reported as:
Mean · s
Change From Baseline in 4-Meter Walk Time (Gait Speed)
sDenosumabZoledronic Acid
Change From Baseline in 4-Meter Walk Time (Gait Speed)-0.46 ± 0.58-0.28 ± 0.60
PrimaryChange From Baseline in Rectus Femoris Muscle Thickness (cm)

This variable will be measured by ultrasound

Time frame:
Baseline vs Month 12
Reported as:
Mean · cm
Change From Baseline in Rectus Femoris Muscle Thickness (cm)
cmDenosumabZoledronic Acid
Change From Baseline in Rectus Femoris Muscle Thickness (cm)0.02 ± 0.110.02 ± 0.12
PrimaryChange From Baseline in Rectus Femoris Muscle Cross-sectional Surface Area (cm²)

This variable will be measured by ultrasound

Time frame:
Baseline vs Month 12
Reported as:
Mean · cm²
Change From Baseline in Rectus Femoris Muscle Cross-sectional Surface Area (cm²)
cm²DenosumabZoledronic Acid
Change From Baseline in Rectus Femoris Muscle Cross-sectional Surface Area (cm²)0.15 ± 0.390.14 ± 0.18
PrimaryCTX Changes

Marker of bone resorption

Time frame:
Baseline vs Month 12
Reported as:
Mean · pg/ml
CTX Changes
pg/mlDenosumabZoledronic Acid
CTX Changes-326.1 ± 128.8-266.6 ± 223.6

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid0/10 (0%)0/10 (0%)0/10 (0%)
Denosumab0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)DenosumabZoledronic AcidTotal
<=18 years000
Between 18 and 65 years000
>=65 years101020
Sex: Female, Male
Sex: Female, Male(Participants)DenosumabZoledronic AcidTotal
Female101020
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DenosumabZoledronic AcidTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9918
More than one race101
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)DenosumabZoledronic AcidTotal
United States101020
Grip Strength
Grip Strength(Kg)DenosumabZoledronic AcidTotal
Mean17.2 ± 3.718.3 ± 4.317.75 ± 3.99
08

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2023 to primary completion in Jan 2026, 34 months.

Results were first posted in Oct 2026, 9 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Dec 27, 2022
StartActual
Feb 14, 2023
Primary completionActual
Jan 5, 2026
CompletionActual
Aug 4, 2026was Sep 2026
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Results
Results posted
posted Oct 27, 2026
Study completion
Sep 5, 2026→Aug 4, 2026 (actual)
Oct 27, 2026
Primary outcomes
6 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedPercentage change from baselineChange From Baseline in muscle mass (kg) measured byUrinary D3-Creatinecreatinine Enrichment (D3-creatine Dilution)Time frame: Baseline vs Month 12
  • EditedPercentage change from baselineChange From Baseline in appendicular lean massBone Mineral Density (ALM/body mass indexBMD)Time frame: Baseline vs Month 12
  • EditedPercentage change from baselineChange From Baseline in trabecular bone score4-Meter Walk Time (TBSGait Speed)Time frame: Baseline vs Month 12
  • EditedPercentage change from baselineChange From Baseline in grip strength (kgf)Grip StrengthTime frame: Baseline vs Month 12
  • EditedPercentage change from baselineChange From Baseline in gait speedRectus Femoris Muscle Thickness (m/scm)Time frame: Baseline vs Month 12
  • EditedPercentage change from baselineChange From Baseline in rectus femoris muscle thicknessRectus Femoris Muscle Cross-sectional Surface Area (cmcm²)Time frame: Baseline vs Month 12
  • AddedChange From Baseline in Appendicular Lean Mass.Time frame: Baseline vs Month 12
  • AddedCTX ChangesTime frame: Baseline vs Month 12
  • RemovedPercentage change from baseline in bone mineral density (BMD) (g/cm²)Time frame: Baseline vs Month 12
  • RemovedPercentage change from baseline in rectus femoris muscle cross-sectional surface area (cm²)Time frame: Baseline vs Month 12
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Results posted
    Study completion Sep 5, 2026→Aug 4, 2026 (now actual)
    Primary outcomes 6 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedPercentage change from baselineChange From Baseline in muscle mass (kg) measured byUrinary D3-Creatinecreatinine Enrichment (D3-creatine Dilution)Time frame: Baseline vs Month 12
    • EditedPercentage change from baselineChange From Baseline in appendicular lean massBone Mineral Density (ALM/body mass indexBMD)Time frame: Baseline vs Month 12
    • EditedPercentage change from baselineChange From Baseline in trabecular bone score4-Meter Walk Time (TBSGait Speed)Time frame: Baseline vs Month 12
    • EditedPercentage change from baselineChange From Baseline in grip strength (kgf)Grip StrengthTime frame: Baseline vs Month 12
    • EditedPercentage change from baselineChange From Baseline in gait speedRectus Femoris Muscle Thickness (m/scm)Time frame: Baseline vs Month 12
    • EditedPercentage change from baselineChange From Baseline in rectus femoris muscle thicknessRectus Femoris Muscle Cross-sectional Surface Area (cmcm²)Time frame: Baseline vs Month 12
    • AddedChange From Baseline in Appendicular Lean Mass.Time frame: Baseline vs Month 12
    • AddedCTX ChangesTime frame: Baseline vs Month 12
    • RemovedPercentage change from baseline in bone mineral density (BMD) (g/cm²)Time frame: Baseline vs Month 12
    • RemovedPercentage change from baseline in rectus femoris muscle cross-sectional surface area (cm²)Time frame: Baseline vs Month 12
    + 4 other changes: verification date, arm descriptions, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05666310
Lead sponsor
Nami Safai Haeri
Collaborators
The Claude D. Pepper Older Americans Independence Centers, National Institute on Aging (NIA)
Responsible party
Nami Safai Haeri (Assistant Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Dec 27, 2022
Start date
Feb 14, 2023
Primary completion
Jan 5, 2026
Completion
Aug 4, 2026
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Nami Safai Haeri, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Denosumab · Zoledronic Acid

Start the discussion